ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis.
about
Drug induced exfoliative dermatitis: state of the artReport from the National Institute of Allergy and Infectious Diseases workshop on drug allergy.Phenytoin-induced toxic epidermal necrolysis: Review and recommendationsStevens-johnson syndrome associated with drugs and vaccines in children: a case-control studyDrug reaction with eosinophilia and systemic symptoms (DRESS): incidence, pathogenesis and management.Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry.Drug-specific upregulation of CD137 on CD8+ T cells aids in the diagnosis of multiple antibiotic toxic epidermal necrolysis.Diclofenac-serratiopeptidase combination induced stevens - johnson syndrome - a rare case report with review of literature.The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis.Lamotrigine-induced toxic epidermal necrolysis confirmed by in vitro granulysin and cytokine assays.Severe cutaneous adverse drug reactions.Allopurinol induced stevens - johnson syndrome - a case report.Fatal Nevirapine-Induced Toxic Epidermal Necrolysis in a HIV Infected Patient.HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children.Phenotype standardization for immune-mediated drug-induced skin injury.Revisiting cutaneous adverse reactions to pemetrexedIron complex, dabigatran and toxic epidermal necrolysis syndrome: a case-report.Stevens-Johnson syndrome / toxic epidermal necrolysis: an Asia-Pacific perspective.Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis: a comparative review.Purpura Fulminans in Toxic Epidermal Necrolysis: Case Report and Review.Recent advances of pharmacogenomics in severe cutaneous adverse reactions: immune and nonimmune mechanisms.Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Update.Patch testing in non-immediate cutaneous adverse drug reactions: value of extemporaneous patch tests.Epidermal necrolysis: 60 years of errors and advances.Old dog begging for new tricks: current practices and future directions in the diagnosis of delayed antimicrobial hypersensitivity.U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016.Recent advances in the understanding of severe cutaneous adverse reactions.Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice.Spontaneous adverse event reports of Stevens-Johnson syndrome/toxic epidermal necrolysis: detecting associations with medications.Impact of an Integrated Antibiotic Allergy Testing Program on Antimicrobial Stewardship: A Multicenter Evaluation.Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study.Poor reporting and documentation in drug-associated Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis - Lessons for medication safety.More than skin deep. Ten year follow-up of delayed cutaneous adverse drug reactions (CADR)Drug-induced liver injury associated with Stevens-Johnson syndrome/toxic epidermal necrolysis: Patient characteristics, causes, and outcome in 36 cases.Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Associations, Outcomes, and Pathobiology-Thirty Years of Progress but Still Much to Be Done.Life-threatening dermatologic adverse events in oncologyIs acetaminophen associated with a risk of Stevens Johnson Syndrome and Toxic Epidermal Necrolysis? Analysis of the French Pharmacovigilance database.Oxcarbazepine-induced Stevens-Johnson syndrome: a pediatric case report.Tolerated drugs in subjects with severe cutaneous adverse reactions (SCARs) induced by anticonvulsants and review of the literature.Incidence, causative drugs, and economic consequences of drug-induced SJS, TEN, and SJS-TEN overlap and potential drug-drug interactions during treatment: a retrospective analysis at an Indonesian referral hospital.
P2860
Q26739886-AB7AE9DB-C177-487E-9A2B-B42E0CC383DFQ26800964-862F8481-D24E-4E5C-B07C-F564FA438DA9Q28074656-DC5F52BC-5970-4BA0-BAEB-9FB8994B1858Q28534684-1DEFA096-DC45-41BF-9FBD-19477B75F50CQ30240144-6868FE48-BA56-44CF-8F1E-1747CC0E490EQ31033074-1A35700E-44A0-4438-9C78-2024D17EB401Q33703420-01B8664E-2924-48E0-8084-25822AD3C160Q34108597-901ED71C-5593-4D3B-8FBB-F116FFF3C8CEQ34225850-F3D26436-A3C9-4F03-B348-BE6E7A02B230Q34432051-8A9D7233-A11B-447F-A593-20D2AB1F9ACEQ34525532-E0557E8C-8C82-4ACC-A4A7-06663322BA65Q35230580-5C48D503-4353-43E9-8F88-6569AB26DB6AQ36831046-2DD2D5EC-D971-4F32-B72F-F9D5BC8F2BC1Q37341208-1470C83D-8BE2-4EDE-9E1C-FA458A11F621Q37874437-105B2E75-8F0A-4482-9E53-8683131C9242Q38032280-DD2374A2-0C93-41AB-9445-6B6C971A473BQ38067456-41639335-777F-4199-BE3A-790DA3E4C1C1Q38164730-5FCA2E3E-B506-4B8D-BDAC-C7C7CA05DFAEQ38225782-61ED413C-603C-4E9B-8AA3-F1C7CA664D32Q38269913-DB92D0C3-8BB7-4988-A45A-76CA70A3A4EFQ38457053-3158FCBF-469F-4C8E-B071-F2A10D5CC9E4Q38611191-DA0B13BF-F12D-4F2C-A2DF-46AAB252AB04Q38668592-C85524F2-3128-45B8-8F22-2D88FC1B1F87Q38697444-094F2823-3F6B-418D-8BD3-9B90B970395CQ38805641-A951551F-953F-41D1-B296-281BCB58D2B4Q38851480-3BD202AD-F8B0-48A3-BE76-4EC5E150B08AQ38931289-E0819BDC-6194-4674-A8A6-5929F8B75B1CQ39291741-D49882CA-AC82-4799-B4C0-62135F02DB3BQ39679666-4B3471A5-1623-446E-A4B2-DF080EE84708Q40207596-0F7F9167-0D05-4817-BD49-CD5A79C39B96Q40241303-D0E61850-763F-4D08-B76E-7B0138BC9CDFQ40563771-36EC0F70-A0EA-4D47-8057-7F03E3FB34A0Q40644493-3EE6EC42-DD8B-48F9-8380-1BF7F439AE93Q40965073-A5FA10F4-26E7-4320-934D-B77AD9C959FEQ41494133-873FE6CF-C654-4077-8FE5-0C07949F6588Q41869634-F5B59BE3-0C3D-486E-8E76-A01B968EB9C6Q41928557-6786FEDD-DA2E-4F41-A03D-E9CC7B095733Q42233812-9F0A5628-1614-4487-8193-CFCD84BEA2B4Q42281124-6019DD49-D40B-4629-92EA-D0F7957B6E15Q42339143-D75D4A3E-E158-4091-9399-162BD0F674BA
P2860
ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
ALDEN, an algorithm for assess ...... on with case-control analysis.
@ast
ALDEN, an algorithm for assess ...... on with case-control analysis.
@en
ALDEN, an algorithm for assess ...... on with case-control analysis.
@nl
type
label
ALDEN, an algorithm for assess ...... on with case-control analysis.
@ast
ALDEN, an algorithm for assess ...... on with case-control analysis.
@en
ALDEN, an algorithm for assess ...... on with case-control analysis.
@nl
prefLabel
ALDEN, an algorithm for assess ...... on with case-control analysis.
@ast
ALDEN, an algorithm for assess ...... on with case-control analysis.
@en
ALDEN, an algorithm for assess ...... on with case-control analysis.
@nl
P2093
P356
P1476
ALDEN, an algorithm for assess ...... on with case-control analysis.
@en
P2093
B Sassolas
H Le Louet
J C Roujeau
M Mockenhaupt
U F Haustein
P2888
P356
10.1038/CLPT.2009.252
P407
P577
2010-04-07T00:00:00Z
P5875
P6179
1027332940